Key result
Novel 4-protein plasma panel identifies primary cardiomyopathy with ~0.99 AUC versus healthy controls.
Why the study?
Primary cardiomyopathy poses diagnostic challenges due to phenotypic heterogeneity and non-specific presentation, while common circulating biomarkers lack disease specificity.
Case-Control (n=81)
Single-blind
No
Effect estimate: AUC 0.993
An integrative Mendelian randomization and clinical validation study identified a 4-protein plasma panel with high diagnostic discrimination for primary cardiomyopathy.
Requires prospective validation before any diagnostic use; leaves open panel performance in larger, diverse cardiomyopathy cohorts.
BACKGROUND: Primary (non-ischemic) cardiomyopathy poses diagnostic challenges due to phenotypic heterogeneity and non-specific clinical presentation, and commonly used circulating biomarkers have limited disease specificity. The aim was to prioritize mechanism-informed plasma biomarkers and evaluate their diagnostic discrimination in a clinical cohort. METHODS: pQTL data from 8 proteomic studies covering 5,034 proteins were integrated, and Mendelian randomization was performed across 3 cardiomyopathy GWAS datasets. Top MR candidates were clinically validated by enzyme-linked immunosorbent assays quantification in a prospective case-control cohort of 81 subjects (48 cardiomyopathy patients and 33 healthy controls). Echocardiography evaluated cardiac function and remodeling, correlating with plasma biomarker levels. RESULTS: Proteome-wide MR prioritized 27 proteins linked to cardiomyopathy risk. Clinical validation confirmed significant differences in plasma levels of 5 selected biomarkers (CD163, LGALS3BP, FABP5, FSTL3, VCAM1). CD163 (odds ratio (OR) = 1.019, P < .0001) was positively associated with CM, while LGALS3BP (OR = 0.390, P < .0001), FABP5, FSTL3, and VCAM1 showed inverse associations. Multivariate analysis revealed CD163 and LGALS3BP as independent CM predictors, strongly correlating with echocardiographic indices of cardiac dysfunction. Receiver operating characteristic analyses showed individual area under the curve (AUC) ranging from 0.632 (VCAM1) to 0.917 (CD163). Given the modest discrimination of VCAM1, 5- versus 4-protein combined models were compared, and a parsimonious 4-protein panel was selected (CD163, LGALS3BP, FABP5, FSTL3). The 4-protein panel achieved an apparent AUC of 0.993, with optimism-corrected and repeated cross-validated AUCs of 0.988 and 0.980. CONCLUSION: This integrative genetic-to-clinical approach supports a 4-protein plasma panel with promising diagnostic discrimination for primary cardiomyopathy, warranting external validation. CD163 and LGALS3BP emerged as particularly informative markers for further evaluation.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) conducted a case-control in Primary cardiomyopathy (n=81). 4-protein plasma panel (CD163, LGALS3BP, FABP5, FSTL3) vs. Healthy controls was evaluated on Diagnostic discrimination for primary cardiomyopathy (AUC 0.993). A 4-protein plasma panel (CD163, LGALS3BP, FABP5, FSTL3) achieved an apparent AUC of 0.993 for the diagnostic discrimination of primary cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: